Whoop's Unauthorized Blood Pressure Tool

This episode shows Whoop pushing its consumer wellness product into medical territory faster than regulators were willing to allow. Blood Pressure Insights was launched alongside Whoop MG as a daily cuff calibrated blood pressure estimate inside the app, while the FDA said those claims made it an unauthorized medical device. Whoop kept the feature live and argued it was a wellness tool, turning one product launch into a test of how far a wearable brand can stretch before formal clearance becomes necessary.1 2 3 4 5

• The practical issue is not just labeling. Users answer a questionnaire, do a one time cuff calibration, then receive daily systolic and diastolic estimates in app. That looks and feels like a blood pressure monitor workflow, which is why the FDA treated it differently from a general recovery score or sleep trend.2 3 4
• Whoop drew a sharp line between features. Its ECG on Whoop MG received FDA 510(k) clearance in April 2025, while Blood Pressure Insights launched the next month without authorization. That split makes clear the company knew how to pursue clearance when it wanted a medical claim, and chose a faster path for blood pressure.3 5 6
• The standoff did not last forever. The FDA first sent a warning letter on July 14, 2025, then issued a broader safety communication on September 16, 2025 warning against unauthorized wearable blood pressure features. On June 17, 2026, the FDA sent a closeout letter after product and labeling changes, saying it did not intend to enforce requirements for the modified version.1 2 5

Going forward, health wearables will keep adding higher value features like blood pressure, ECG, and lab based risk scoring, but the winners will be the ones that match product ambition with regulatory discipline. Whoop now has a clearer playbook, launch fast in wellness where possible, but secure authorization or narrow claims before a feature starts behaving like a medical device.1 3 5 6